+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Chronic Refractory Cough Market by Drug Class, Route of Administration, Distribution Channel, End User - Global Forecast to 2030- Product Image
Chronic Refractory Cough Market by Drug Class, Route of Administration, Distribution Channel, End User - Global Forecast to 2030- Product Image
Sale

Chronic Refractory Cough Market by Drug Class, Route of Administration, Distribution Channel, End User - Global Forecast to 2030

  • PDF Icon

    Report

  • 182 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5968261
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The chronic refractory cough market is undergoing pivotal transformation as targeted therapies, regulatory shifts, and evolving care models converge to redefine treatment landscapes. Senior decision-makers need timely, actionable intelligence to position their organizations in this changing environment while balancing cost, access, and innovation.

Market Snapshot: Chronic Refractory Cough Market Overview

The Chronic Refractory Cough Market grew from USD 5.88 billion in 2024 to USD 6.23 billion in 2025. It is expected to continue growing at a CAGR of 5.95%, reaching USD 8.32 billion by 2030. This reflects consistent market expansion driven by increased innovation in drug development, enhanced diagnostic tools, and the rise of precision medicine approaches within chronic cough management.

Scope & Segmentation

This report offers deep analysis and forecasts across the entire chronic refractory cough value chain in major global regions, supporting more informed investment, pipeline, and partnership decisions.

  • Drug Classes: Neuromodulators, Opioid Antagonists, P2X3 Antagonists
  • Routes of Administration: Inhalation, Injectable, Oral
  • Distribution Channels: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies
  • End User Types: Homecare, Hospitals, Specialty Clinics
  • Geographic Focus: Americas (United States – including California, Texas, New York, Florida, Illinois, Pennsylvania, Ohio; Canada; Mexico; Brazil; Argentina), Europe, Middle East & Africa (e.g., United Kingdom, Germany, France, Saudi Arabia, South Africa, Nigeria, Israel, and others), Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Vietnam, and other leading markets)
  • Company Developments: Strategic moves by Merck & Co., Inc.; Bayer AG; Bellus Health Inc.; Shionogi & Co., Ltd.; Johnson & Johnson; GlaxoSmithKline plc; Sanofi S.A.; Pfizer Inc.; Teva Pharmaceutical Industries Ltd.; Novartis AG

Key Takeaways for Senior Decision-Makers

  • Heightened cough reflex sensitivity and limited treatment responsiveness create a persistent unmet need, amplifying demand for innovative therapies and personalized care.
  • Breakthroughs with neuromodulators and P2X3 antagonists are reshaping the drug development pipeline, increasing commercial prospects for new entrants and established players alike.
  • Digital health adoption enables real-time symptom monitoring, facilitating improved clinical trial design and patient-tailored interventions throughout chronic refractory cough management.
  • Distribution models are evolving as online pharmacies and homecare expand patient access, while hospital and specialty channels support advanced therapies and clinical trials.
  • Partnerships across pharmaceutical and technology sectors accelerate holistic patient solutions, including enhanced remote support and outcome measurement.
  • Regional reimbursement frameworks, especially in the Americas, foster earlier uptake of next-generation therapies, while diverse regulatory timelines in EMEA and Asia-Pacific necessitate adaptive go-to-market strategies.

Tariff Impact: US Trade Policy Shaping Supply Chains and Access

Recent US tariffs have affected supply chain strategies by increasing costs for active pharmaceutical ingredients sourced abroad. Manufacturers responded by relocating production to manage expenses and protect margins. Payer scrutiny intensified, with tighter access parameters in select regions. Value-based pricing and close collaboration with pharmacy benefit managers became critical to maintaining both patient access and financial performance. The industry now emphasizes resilient, agile supply chains and proactive procurement strategies to adapt to ongoing trade policy volatility.

Methodology & Data Sources

This market research incorporates secondary data analysis, primary interviews with industry experts, and robust data triangulation. Sources include peer-reviewed journals, regulatory filings, clinical trial registries, and structured interviews with key opinion leaders, executives, and payers. Quantitative modeling and scenario analysis underpin all findings and recommendations.

Why This Report Matters: Actionable Value for Stakeholders

  • Provides strategic insights into evolving drug classes, new therapies, and regional shifts, enabling more informed executive decision-making.
  • Guides supply chain, pricing, and market access strategies through grounded analysis of tariff impacts, regulatory variations, and distribution advancements.
  • Equips teams with segmentation and trend intelligence needed for optimizing investments, partnerships, and competitive positioning in the chronic refractory cough market.

Conclusion

As the landscape for chronic refractory cough evolves, industry leaders with clear, data-driven insights will be poised to navigate complexity and drive sustainable growth. This report delivers a critical foundation for seizing emerging opportunities, improving access, and advancing patient-centered innovation.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Chronic Refractory Cough Market, by Drug Class
8.1. Introduction
8.2. Neuromodulators
8.3. Opioid Antagonists
8.4. P2X3 Antagonists
9. Chronic Refractory Cough Market, by Route of Administration
9.1. Introduction
9.2. Inhalation
9.3. Injectable
9.4. Oral
10. Chronic Refractory Cough Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacies
10.3. Online Pharmacies
10.4. Retail Pharmacies
11. Chronic Refractory Cough Market, by End User
11.1. Introduction
11.2. Homecare
11.3. Hospitals
11.4. Specialty Clinics
12. Americas Chronic Refractory Cough Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Chronic Refractory Cough Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Chronic Refractory Cough Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Merck & Co., Inc.
15.3.2. Bayer AG
15.3.3. Bellus Health Inc.
15.3.4. Shionogi & Co., Ltd.
15.3.5. Johnson & Johnson
15.3.6. GlaxoSmithKline plc
15.3.7. Sanofi S.A.
15.3.8. Pfizer Inc.
15.3.9. Teva Pharmaceutical Industries Ltd.
15.3.10. Novartis AG
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. CHRONIC REFRACTORY COUGH MARKET MULTI-CURRENCY
FIGURE 2. CHRONIC REFRACTORY COUGH MARKET MULTI-LANGUAGE
FIGURE 3. CHRONIC REFRACTORY COUGH MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS CHRONIC REFRACTORY COUGH MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS CHRONIC REFRACTORY COUGH MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES CHRONIC REFRACTORY COUGH MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES CHRONIC REFRACTORY COUGH MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CHRONIC REFRACTORY COUGH MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CHRONIC REFRACTORY COUGH MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC CHRONIC REFRACTORY COUGH MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC CHRONIC REFRACTORY COUGH MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. CHRONIC REFRACTORY COUGH MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. CHRONIC REFRACTORY COUGH MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. CHRONIC REFRACTORY COUGH MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY NEUROMODULATORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY OPIOID ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY P2X3 ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY INHALATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY HOMECARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. AMERICAS CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 23. AMERICAS CHRONIC REFRACTORY COUGH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 24. AMERICAS CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 25. AMERICAS CHRONIC REFRACTORY COUGH MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 26. AMERICAS CHRONIC REFRACTORY COUGH MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 27. UNITED STATES CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 28. UNITED STATES CHRONIC REFRACTORY COUGH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 29. UNITED STATES CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 30. UNITED STATES CHRONIC REFRACTORY COUGH MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 31. UNITED STATES CHRONIC REFRACTORY COUGH MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 32. CANADA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 33. CANADA CHRONIC REFRACTORY COUGH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 34. CANADA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 35. CANADA CHRONIC REFRACTORY COUGH MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 36. MEXICO CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 37. MEXICO CHRONIC REFRACTORY COUGH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 38. MEXICO CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 39. MEXICO CHRONIC REFRACTORY COUGH MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 40. BRAZIL CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 41. BRAZIL CHRONIC REFRACTORY COUGH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 42. BRAZIL CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 43. BRAZIL CHRONIC REFRACTORY COUGH MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 44. ARGENTINA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 45. ARGENTINA CHRONIC REFRACTORY COUGH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 46. ARGENTINA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 47. ARGENTINA CHRONIC REFRACTORY COUGH MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 48. EUROPE, MIDDLE EAST & AFRICA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 49. EUROPE, MIDDLE EAST & AFRICA CHRONIC REFRACTORY COUGH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 50. EUROPE, MIDDLE EAST & AFRICA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 51. EUROPE, MIDDLE EAST & AFRICA CHRONIC REFRACTORY COUGH MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 52. EUROPE, MIDDLE EAST & AFRICA CHRONIC REFRACTORY COUGH MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 53. UNITED KINGDOM CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 54. UNITED KINGDOM CHRONIC REFRACTORY COUGH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 55. UNITED KINGDOM CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 56. UNITED KINGDOM CHRONIC REFRACTORY COUGH MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 57. GERMANY CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 58. GERMANY CHRONIC REFRACTORY COUGH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 59. GERMANY CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 60. GERMANY CHRONIC REFRACTORY COUGH MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 61. FRANCE CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 62. FRANCE CHRONIC REFRACTORY COUGH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 63. FRANCE CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 64. FRANCE CHRONIC REFRACTORY COUGH MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 65. RUSSIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 66. RUSSIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 67. RUSSIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 68. RUSSIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 69. ITALY CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 70. ITALY CHRONIC REFRACTORY COUGH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 71. ITALY CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 72. ITALY CHRONIC REFRACTORY COUGH MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 73. SPAIN CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 74. SPAIN CHRONIC REFRACTORY COUGH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 75. SPAIN CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 76. SPAIN CHRONIC REFRACTORY COUGH MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 77. UNITED ARAB EMIRATES CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 78. UNITED ARAB EMIRATES CHRONIC REFRACTORY COUGH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 79. UNITED ARAB EMIRATES CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 80. UNITED ARAB EMIRATES CHRONIC REFRACTORY COUGH MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 81. SAUDI ARABIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 82. SAUDI ARABIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 83. SAUDI ARABIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 84. SAUDI ARABIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 85. SOUTH AFRICA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 86. SOUTH AFRICA CHRONIC REFRACTORY COUGH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 87. SOUTH AFRICA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 88. SOUTH AFRICA CHRONIC REFRACTORY COUGH MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 89. DENMARK CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 90. DENMARK CHRONIC REFRACTORY COUGH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 91. DENMARK CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 92. DENMARK CHRONIC REFRACTORY COUGH MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 93. NETHERLANDS CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 94. NETHERLANDS CHRONIC REFRACTORY COUGH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 95. NETHERLANDS CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 96. NETHERLANDS CHRONIC REFRACTORY COUGH MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 97. QATAR CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 98. QATAR CHRONIC REFRACTORY COUGH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 99. QATAR CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 100. QATAR CHRONIC REFRACTORY COUGH MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 101. FINLAND CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 102. FINLAND CHRONIC REFRACTORY COUGH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 103. FINLAND CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 104. FINLAND CHRONIC REFRACTORY COUGH MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 105. SWEDEN CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 106. SWEDEN CHRONIC REFRACTORY COUGH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 107. SWEDEN CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 108. SWEDEN CHRONIC REFRACTORY COUGH MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 109. NIGERIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 110. NIGERIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 111. NIGERIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 112. NIGERIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 113. EGYPT CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 114. EGYPT CHRONIC REFRACTORY COUGH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 115. EGYPT CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 116. EGYPT CHRONIC REFRACTORY COUGH MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 117. TURKEY CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 118. TURKEY CHRONIC REFRACTORY COUGH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 119. TURKEY CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 120. TURKEY CHRONIC REFRACTORY COUGH MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 121. ISRAEL CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 122. ISRAEL CHRONIC REFRACTORY COUGH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 123. ISRAEL CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 124. ISRAEL CHRONIC REFRACTORY COUGH MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 125. NORWAY CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 126. NORWAY CHRONIC REFRACTORY COUGH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 127. NORWAY CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 128. NORWAY CHRONIC REFRACTORY COUGH MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 129. POLAND CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 130. POLAND CHRONIC REFRACTORY COUGH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 131. POLAND CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 132. POLAND CHRONIC REFRACTORY COUGH MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 133. SWITZERLAND CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 134. SWITZERLAND CHRONIC REFRACTORY COUGH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 135. SWITZERLAND CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 136. SWITZERLAND CHRONIC REFRACTORY COUGH MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 137. ASIA-PACIFIC CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 138. ASIA-PACIFIC CHRONIC REFRACTORY COUGH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 139. ASIA-PACIFIC CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 140. ASIA-PACIFIC CHRONIC REFRACTORY COUGH MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 141. ASIA-PACIFIC CHRONIC REFRACTORY COUGH MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 142. CHINA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 143. CHINA CHRONIC REFRACTORY COUGH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 144. CHINA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 145. CHINA CHRONIC REFRACTORY COUGH MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 146. INDIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 147. INDIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 148. INDIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 149. INDIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 150. JAPAN CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 151. JAPAN CHRONIC REFRACTORY COUGH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 152. JAPAN CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 153. JAPAN CHRONIC REFRACTORY COUGH MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 154. AUSTRALIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 155. AUSTRALIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 156. AUSTRALIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 157. AUSTRALIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 158. SOUTH KOREA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 159. SOUTH KOREA CHRONIC REFRACTORY COUGH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 160. SOUTH KOREA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 161. SOUTH KOREA CHRONIC REFRACTORY COUGH MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 162. INDONESIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 163. INDONESIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 164. INDONESIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 165. INDONESIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 166. THAILAND CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 167. THAILAND CHRONIC REFRACTORY COUGH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 168. THAILAND CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 169. THAILAND CHRONIC REFRACTORY COUGH MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 170. PHILIPPINES CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 171. PHILIPPINES CHRONIC REFRACTORY COUGH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 172. PHILIPPINES CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 173. PHILIPPINES CHRONIC REFRACTORY COUGH MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 174. MALAYSIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 175. MALAYSIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 176. MALAYSIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 177. MALAYSIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 178. SINGAPORE CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 179. SINGAPORE CHRONIC REFRACTORY COUGH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 180. SINGAPORE CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 181. SINGAPORE CHRONIC REFRACTORY COUGH MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 182. VIETNAM CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 183. VIETNAM CHRONIC REFRACTORY COUGH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 184. VIETNAM CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 185. VIETNAM CHRONIC REFRACTORY COUGH MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 186. TAIWAN CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 187. TAIWAN CHRONIC REFRACTORY COUGH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 188. TAIWAN CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 189. TAIWAN CHRONIC REFRACTORY COUGH MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 190. CHRONIC REFRACTORY COUGH MARKET SHARE, BY KEY PLAYER, 2024
TABLE 191. CHRONIC REFRACTORY COUGH MARKET, FPNV POSITIONING MATRIX, 2024

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Chronic Refractory Cough market report include:
  • Merck & Co., Inc.
  • Bayer AG
  • Bellus Health Inc.
  • Shionogi & Co., Ltd.
  • Johnson & Johnson
  • GlaxoSmithKline plc
  • Sanofi S.A.
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Novartis AG

Table Information

Report AttributeDetails
No. of Pages182
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 6.23 Billion
Forecasted Market Value ( USD ) by 2030 $ 8.32 Billion
Compound Annual Growth Rate5.9%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Chronic Refractory Cough - Pipeline Insight, 2025 - Product Image

Chronic Refractory Cough - Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From
Cough In Idiopathic Pulmonary Fibrosis (IPF) - Pipeline Insight,2025 - Product Image

Cough In Idiopathic Pulmonary Fibrosis (IPF) - Pipeline Insight,2025

  • Drug Pipelines
  • 60 Pages
  • Global
From
Expectorant Drugs - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2024 - 2029) - Product Image

Expectorant Drugs - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2024 - 2029)

  • Report
  • 115 Pages
  • Global
From
Cough Syrup Market Report by Product Type, Age Group, Distribution Channel, and Region 2024-2032 - Product Image

Cough Syrup Market Report by Product Type, Age Group, Distribution Channel, and Region 2024-2032

  • Report
  • 136 Pages
  • Global
From
Chronic Cough Market Report 2025 - Product Image

Chronic Cough Market Report 2025

  • Report
  • 200 Pages
  • Global
From

About the Chronic Refractory Cough Drugs Market

The Chronic Refractory Cough Drugs market is a subset of the larger Respiratory Drugs market. It is composed of drugs used to treat chronic refractory cough, a condition characterized by a persistent cough that does not respond to conventional treatments. These drugs are typically used in combination with other treatments, such as lifestyle modifications, to reduce the severity of the cough. Commonly used drugs include anticholinergics, antihistamines, and mucolytics. These drugs are used to reduce inflammation, reduce mucus production, and reduce airway irritation. The Chronic Refractory Cough Drugs market is highly competitive, with many companies offering a variety of products. Some of the major players in the market include GlaxoSmithKline, Merck & Co., Pfizer, AstraZeneca, and Novartis. Other companies include Sanofi, Boehringer Ingelheim, and Sun Pharmaceuticals. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.